Klee Ann R.
Known title: DirectorCIK: 0001796076
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Wabtec Prepares for Q3 Earnings Amid Valuation Concerns. Wabtec is preparing for its upcoming Q3 earnings report, with market commentary focusing on expectations beyond headline estimates. The company recently declared its regular quarterly common dividend, though some analysis suggests the stock may look fully valued against cash flow prospects. Current discussions also include comparisons with peers and key drivers behind investor interest in the company.
Transaction History
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| WAB | ▲ Buy | Grant | 765 | $0 | 5/13/2026 | View on chart |
| SHC | ▲ Buy | Grant | 19,132 | $0 | 5/22/2025 | View on chart |
| WAB | ▲ Buy | Grant | 953 | $0 | 5/16/2025 | View on chart |
| SHC | ▲ Buy | Grant | 20,089 | $0 | 5/24/2024 | View on chart |
| WAB | ▲ Buy | Grant | 1,165 | $0 | 5/16/2024 | View on chart |
| SHC | ▼ Sell | Open Market | 5,750 | $82K | 3/4/2024 | View on chart |
| SHC | ▲ Buy | Grant | 15,712 | $0 | 5/26/2023 | View on chart |
| WAB | ▲ Buy | Grant | 1,857 | $0 | 5/16/2023 | View on chart |
| SHC | ▲ Buy | Grant | 10,643 | $0 | 5/27/2022 | View on chart |
| WAB | ▲ Buy | Grant | 1,817 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.